Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 7% Improvement Relative Risk Ventilation 7% ICU admission -24% Recovery, day 14 28% Recovery, day 7 12% Recovery time 14% Kasiri et al. IRCT20190804044429N5 Colchicine RCT LATE Favors colchicine Favors control
The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial
Kasiri et al., Journal of Investigative Medicine, doi:10.1177/10815589221141815, IRCT20190804044429N5
Kasiri et al., The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled.., Journal of Investigative Medicine, doi:10.1177/10815589221141815, IRCT20190804044429N5
Jan 2023   Source   PDF  
  All Studies   Meta
Very late treatment (10 days from onset) RCT 110 patients in Iran, showing no significant difference in outcomes with colchicine. Colchicine 2mg loading dose followed by 0.5mg bid for 7 days.
risk of death, 7.3% lower, RR 0.93, p = 1.00, treatment 6 of 55 (10.9%), control 6 of 51 (11.8%), NNT 117.
risk of mechanical ventilation, 7.3% lower, RR 0.93, p = 1.00, treatment 6 of 55 (10.9%), control 6 of 51 (11.8%), NNT 117.
risk of ICU admission, 23.6% higher, RR 1.24, p = 0.63, treatment 12 of 55 (21.8%), control 9 of 51 (17.6%).
risk of no recovery, 27.9% lower, RR 0.72, p = 0.59, treatment 7 of 55 (12.7%), control 9 of 51 (17.6%), NNT 20, day 14.
risk of no recovery, 11.7% lower, RR 0.88, p = 0.69, treatment 20 of 55 (36.4%), control 21 of 51 (41.2%), NNT 21, day 7.
recovery time, 14.3% lower, relative time 0.86, p = 0.06, treatment 55, control 51.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kasiri et al., 16 Jan 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, mean age 54.6, 6 authors, study period February 2021 - May 2021, average treatment delay 10.0 days, trial IRCT20190804044429N5.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: Original Article The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial Journal of Investigative Medicine 2023, Vol. 00(0) 1–8 Ó 2023 American Federation for Medical Research Article reuse guidelines: DOI: 10.1177/10815589221141815 Hossein Kasiri1, Mobin Ghazaiean2, Nima Rouhani3, Fahimeh Naderi-behdani1, Monireh Ghazaeian4, and Robabeh Ghodssi-Ghassemabadi5 Abstract This study was designed to evaluate the effects of colchicine in the improvement of clinical outcomes of hospitalized COVID-19 patients. This prospective, randomized, double-blind, placebo-controlled clinical trial was conducted on adult patients (.18 years) with severe COVID-19. The included patients were randomly (1:1) assigned to the colchicine (2 mg loading dose followed by 0.5 mg twice daily for 7 days) or placebo group. Both groups received remdesivir and interferon beta-1b. The primary outcome of the study was to receive clinical response as ordinal scale of 1 or 2. Secondary outcomes were hospital complications and 28-day mortality. Between February and May 2021, 110 patients were included and 106 of them were analyzed. Baseline clinical characteristics and demographics were not significantly different. According to the ordinal scale, 30 patients in the control group (58.8%) responded to treatment within 7 days, while 35 patients (63.6%) in the colchicine group showed the same response (p = 0.61, odds ratio (OR) = 1.23, 95% CI [0.560–2.68]). On the 14th day, 87.3% of the colchicine group (n = 48) and 82.4% of the control group (n = 42) responded (p = 0.48, OR = 1.47, 95% CI [0.50.3–4.29]. In addition, 28-day mortality, intensive care unit admission, and hospital duration were not different between the groups (p = 0.99, 0.59, 0.06). Diarrhea and nausea were the major side effects dominant in the colchicine group. Colchicine showed no beneficial effects on clinical improvement and hospital complications in patients with COVID-19. Moreover, in case of prescription, the safety concerns of colchicine, specially gastrointestinal side effects, should be taken into account. Keywords Colchicine, COVID-19, efficacy
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop